|Phase of Study:||Phase I|
|Treatment Location:||Only at MDACC|
|Estimated Length of Stay in Houston:||No hospitalization is required for this study unless there are patient |
|Supported By:||Bayer HealthCare Pharmaceuticals, Inc.|
Food and Drug Administration (FDA)
Georgia Institute of Technology
National Cancer Institute (NCI)
|Return Visit:||Cycle 1 on day 1, 2, 3, 4, and 5; then weekly. Optional blood draws day 1 at 3 |
time points: hr 0, 5, and 12; and days 2, 4, and 14, and an optional extra
research bone marrow aspiration both before treatment starts and on day 14-17.
|Home Care:||If agreeing to the optional research, presence is required, after the baseline |
visit, on days 1, 2, 4, and 14-17 for sample collections.